Trial Profile
A retropsective study investigating efficacy and safety of Erlotinib as first line therapy in patients with advanced non squamous non small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Oct 2016 New trial record
- 01 Oct 2016 Results published in the Journal of Thoracic Oncology